Belvedere Trading
MLTX icon

Belvedere Trading’s MoonLake Immunotherapeutics MLTX Stock Holding History

Belvedere Trading’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,300
Closed -$57.2K – 845
2024
Q2 		$57.2K Sell
1,300
-900
-41% -$38.1K ﹤0.01% 499
2024
Q1 		$111K Buy
2,200
+400
+22% +$21.7K ﹤0.01% 423
2023
Q4 		$109K Sell
1,800
-400
-18% -$20.6K ﹤0.01% 446
2023
Q3 		$125K Buy
+2,200
New +$121K ﹤0.01% 294

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Belvedere Trading's MLTX Position: Q3 2024 in Review

Belvedere Trading sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2024, closing a stake of 2,860 shares — an estimated $126K sold.

Belvedere Trading first reported a position in MLTX in Q3 2023 and held it in 3 quarters. The position peaked at $224K in Q3 2023. 109 funds tracked by Wall St. Rank hold MLTX as of Q3 2024.

  • Belvedere Trading reported no remaining MoonLake Immunotherapeutics position as of Q3 2024 after selling out during the quarter.
  • Belvedere Trading sold 2,860 MoonLake Immunotherapeutics shares in Q3 2024, an estimated $126K.
  • Belvedere Trading first reported a position in MoonLake Immunotherapeutics in Q3 2023 and held it in 3 quarters.
  • Belvedere Trading's MoonLake Immunotherapeutics position peaked at $224K in Q3 2023.
  • 109 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2024.

Based on Belvedere Trading's 13F filing for Q3 2024, filed 30 Oct 2024.